Watson's major challenge with this work is matching a patient's specific mutation to the correct journal articles describing that mutation.
"You will find over time that because of the complexity of the mutations, the medical research will provide more options that are specific to that patient," Singh said.
Singh said that Watson, like any knowledge-based system, will learn over time and get better at providing relevant information. "As we work with partners, we will learn how the drug treatments have been applied and the outcome of patients," Singh said. As a result, Watson "will continuously improve the accuracy" of its results, he predicted.
Singh predicted that Watson will learn this information quickly. "We're very much hoping to scale the use of this [to commercial use] over a period of months rather than years," Singh said.
The New York Genome Center is a nonprofit biomedical research and clinical care facility funded by a consortium of medical and academic facilities, including the Memorial Sloan-Kettering Cancer Center, New York University and The Rockefeller University.
Sign up for MIS Asia eNewsletters.